1211527-75-1

Basic information

• Product Name: (2,4-difluorophenyl)methyl isothiourea hydrochloride
• CAS NO: 1211527-75-1
• Molecular Weight: 238.689
• Mol File: 1211527-75-1.mol

Chemical Properties

• CAS DataBase Reference: (2,4-difluorophenyl)methyl isothiourea hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (2,4-difluorophenyl)methyl isothiourea hydrochloride(1211527-75-1)
• EPA Substance Registry System: (2,4-difluorophenyl)methyl isothiourea hydrochloride(1211527-75-1)

Safety Data

• Hazardous Substances Data: 1211527-75-1(Hazardous Substances Data)

Upstream product

• 452-07-3 2,4-difluorobenzyl chloride 
• 17356-08-0 thiourea 

Downstream Products

• 1001026-56-7 1-(2,4-difluorphenyl)methanesulfonamide 
• 179524-68-6 (2,4-difluorophenyl)methanesulfonyl chloride 

Relevant articles and documents

Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties

P2Y12 antagonists are widely used as antiplatelet agents for the prevention and treatment of arterial thrombosis. Based on the scaffold of a known P2Y12 antagonist AZD1283, a series of novel bicyclic pyridine derivatives were designed and synthesized. The cyclization of the ester substituent on the pyridine ring to the ortho-methyl group led to lactone analogues of AZD1283 that showed significantly enhanced metabolic stability in subsequent structure-pharmacokinetic relationship studies. The metabolic stability was further enhanced by adding a 4-methyl substituent to the piperidinyl moiety. Compound 58l displayed potent inhibition of platelet aggregation in vitro as well as antithrombotic efficacy in a rat ferric chloride model. Moreover, 58l showed a safety profile that was superior to what was observed for clopidogrel in a rat tail-bleeding model. These results support the further evaluation of compound 58l as a promising drug candidate.

INHIBITION OF CELL PROLIFERATION

Compounds of formula (I) and (II) are provided as modulators of Rb:Raf-1 interactions which are potent, selective disruptors of Rb:Raf-1 binding. Therapeutic methods of using the compounds, for example for treating or ameliorating a cell proliferation disorder such as cancer, are provided.